Patent classifications
C07D231/46
Methods and compositions associated with the granulocyte colony-stimulating factor receptor
Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
Reaction accelerating agent
Provided is a compound which accelerates the enzymatic reaction catalyzed by an oxidase. The present invention provides an oxidase reaction accelerating agent comprising a compound represented by formula (I) and a method using the same.
Reaction accelerating agent
Provided is a compound which accelerates the enzymatic reaction catalyzed by an oxidase. The present invention provides an oxidase reaction accelerating agent comprising a compound represented by formula (I) and a method using the same.
Highly stable crystalline Eltrombopag monoethanolamine salt form D1
Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.
Highly stable crystalline Eltrombopag monoethanolamine salt form D1
Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.
HIGHLY STABLE CRYSTALLINE ELTROMBOPAG MONOETHANOLAMINE SALT FORM D1
Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.
HIGHLY STABLE CRYSTALLINE ELTROMBOPAG MONOETHANOLAMINE SALT FORM D1
Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.
Solid state forms of eltrombopag choline
Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.
Solid state forms of eltrombopag choline
Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.
An improved process for the preparation of Eltrombopag Olamine and its intermediates
The present invention relates to an improved process for the purification of Eltrombopag olamine of compound of formula (2). The present invention also relates to an improved process for the preparation of Eltrombopag olamine intermediates and further conversion to Eltrombopag olamine of a compound of formula (2).
##STR00001##